IL-33 Targeting Shows Promise in COPD Treatment
Recent studies highlight IL-33 inhibition as a promising approach to reduce exacerbations in COPD patients. Tozorakimab, an IL-33 inhibitor, is poised to impact the COPD market by addressing inflammation and mucus plugs. Ongoing research explores which patient groups benefit most and what aspects remain unclear, with expert insights from Dr. Francesca Polverino.
HCPLive·


